A pair of infectious disease specialists at the University of Calgary have launched a national coalition aimed at preventing what they say could be a return to rising rates of HIV in Canada and abroad.
New consortium targets shifting global HIV landscape
Dr. M. John Gill and Dr. Raynell Lang formed the Canadian Strategic Consortium to Address the Changing Policies and Environment of Global HIV Care (CanSCAPE‑HIV) to co‑ordinate research, policy advice and clinical pathways as international funding changes alter prevention and treatment programmes overseas.
Globally, advances in antiretroviral therapy have transformed HIV from a fatal disease to a chronic, manageable condition for many people: daily medication can restore life expectancy close to population norms and reduce infectiousness to near zero. But Gill and Lang warn that a sharp reduction in international aid beginning in January 2025, led by funding cuts from the United States, has created conditions that could reverse those gains in some countries.
“The rapidity and the sudden (loss of global aid) has caused no end of challenges. Cutting back on funding means that we're unleashing an epidemic where it has been well controlled,”
Gill told reporters the cuts risk a cascade of negative effects: interruptions to treatment, erosion of prevention programming, rising stigma and misinformation, and in some jurisdictions even criminalization of people living with HIV. Those outcomes, he said, can produce delayed access to care and ultimately greater human and fiscal costs.
Local implications for Alberta and newcomers to Canada
CanSCAPE‑HIV emphasises that the consequences of weakened global control are not confined to distant countries. The consortium’s founders caution that increases in incidence abroad could translate into more people arriving in Canada with untreated or newly acquired infections—and that Canada must be ready to integrate them safely into care.
Under existing immigration procedures, people arriving in Canada are screened for HIV as part of the medical assessment. A positive result does not automatically bar entry; rather, it should trigger a pathway to treatment and follow‑up. Gill said that in practice some newcomers receive only a few days’ worth of medication and are expected to locate care on their own. CanSCAPE‑HIV wants those transitions to be systematic and reliable.
- CanSCAPE‑HIV will focus on prevention, rapid linkage to care, and policy recommendations.
- Founders warn of program disruptions following international funding cuts that began January 2025.
- Consortium stresses need for coordinated services for newcomers diagnosed through immigration screening.
Costs, prevention and public‑health strategy
The consortium points to the economics of early, sustained treatment. Routine antiretroviral regimens used in well‑resourced health systems can cost up to $1,500 a month per person, but the group argues that the costs of uncontrolled HIV—advanced illness, opportunistic infections, and social instability—are far greater and more difficult to manage.
| Item | Detail |
|---|---|
| Typical drug cost (per month) | $1,500 |
| Triggering event | Global funding cuts starting January 2025 |
Beyond medication costs, the consortium underscores the public‑health logic of prevention and stable care: maintaining programmes in low‑ and middle‑income countries is cheaper and more effective than addressing uncontrolled outbreaks later. Where services and information are absent, they say, stigma and misinformation fill the void—hindering testing and treatment uptake.
What this means for clinicians and policymakers
CanSCAPE‑HIV plans to gather data, model potential scenarios and propose policy responses tailored to Canada’s health systems, including provincial programs. That could include recommendations on screening follow‑up, access to publicly funded therapy for newcomers, and community outreach strategies aimed at reducing stigma and improving early engagement in care.
In Alberta, where public‑health and primary care systems already manage HIV services, the consortium’s work may inform provincial planning—particularly in Calgary and Edmonton where larger newcomer populations settle.
The group’s formation is a pre‑emptive move: rather than waiting for a documented rise in cases, Gill and Lang say they want to shore up clinical pathways and policy levers now to prevent avoidable human and economic costs later.
For Albertans, the message is twofold: medical advances have dramatically reduced the individual and public‑health burden of HIV, but those gains are fragile and rely on continuous prevention and treatment efforts at home and abroad.
CanSCAPE‑HIV’s convening will put Alberta clinicians and researchers into a national conversation about how to protect those gains in a rapidly changing global funding environment.
